Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1
The efficacy of immune checkpoint blockade therapy against immunologically “cold” tumors can be enhanced by applying the checkpoint inhibitors in combination with oncolytic viruses. Alternatively, the oncolytic virus construct has been modified to express factors that boost oncolytic virus function....
Main Authors: | Yujie Zhu, Xiao Hu, Lin Feng, Zhenrong Yang, Lulin Zhou, Xinchun Duan, Shujun Cheng, Wen Zhang, Binlei Liu, Kaitai Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-12-01
|
Series: | Molecular Therapy: Oncolytics |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770519300932 |
Similar Items
-
Oncolytic herpes simplex virus and immunotherapy
by: Wenqing Ma, et al.
Published: (2018-12-01) -
A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.
by: Qian Zhao, et al.
Published: (2014-01-01) -
Enhancement of oncolytic herpes simplex type 1 virotherapy
by: Delwar, Zahid M.
Published: (2017) -
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
by: Norah Aldrak, et al.
Published: (2021-06-01) -
The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
by: Nguyen HM, et al.
Published: (2021-02-01)